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ABSTRACT
Background: Cardiovascular complication remains the long-term complications in spondyloarthritis (SpA). Previous studies revealed that metabolic 
syndrome is the risk factor of cardiovascular in SpA patients. Previous studies also revealed that the prevalence of the metabolic syndrome is 34.9–
45.7% in SpA patients. However, previous studies also revealed the controversy of the correlation of SpA’ disease activity with metabolic syndrome.
Aim: The aim of the study was to investigate the correlation of SpA’ radiographical damage measured with a modified Stoke Ankylosing Spondylitis 
Spinal Score (mSASSS) score with metabolic syndrome in SpA patients, which routinely visited Rheumatology Outpatient Department in Dr. Soetomo 
General Hospital.
Methods: An observational study with cross-sectional design with consecutive sampling technique was conducted in July–October 2018. All SpA 
patients who fulfilled the inclusion criteria were included in this study. Data analysis was performed with SPSS v21.0.
Results: There were 33 SpA patients (10 males and 23 females) included in this study. The average age was 48.18±12.27 years-old. The average 
mSASSS score was 24,36 (K:0.93, p:0.00). Metabolic syndrome was diagnosed in 54.5% patients with 100% patients had central obesity, 66.7% had 
increased blood pressure, 61.5% had impaired fasting glucose, 55.6% had increased triglycerides, and 77.8% had decreased high-density lipoprotein 
cholesterol. Positive correlation between mSASSS score and metabolic syndrome was observed (r:0.510, p:0.002).
Conclusion: A correlation between SpA disease activity measured with mSASSS score and metabolic syndrome was observed. Therefore, routine 
metabolic syndrome screening is strongly suggested for SpA patients.
Keywords: Metabolic syndrome, Spondyloarthritis, Modified stoke ankylosing spondylitis spinal score.
BACKGROUND
Spondyloarthritis (SpA) is a chronic inflammatory disorder which 
is related to the presence of HLA-B27. SpA has various clinical 
symptoms ranging from chronic inflammatory back pain, peripheral 
arthritis, to enteropathy arthritis, and uveitis [1,2]. Among its long-
term complication, cardiovascular complications remain the leading 
morbidity and mortality in SpA patients. Previous studies revealed that 
cardiovascular complications risk such as myocardial infarction and 
cerebrovascular accident are accelerated in SpA population [3,4].
One of the cardiovascular risk factors is metabolic syndrome. It 
is a constellation of obesity, insulin resistance, hypertension, and 
dyslipidemia [5]. Mottillo et al. revealed that metabolic syndrome increases 
the risk of cardiovascular complications at least two-fold and all-cause 
mortality by at least 1.5-fold. Previous studies also revealed that the 
prevalence of the metabolic syndrome is increased in SpA patients, ranging 
from 34.9% to 45.7% [6,7]. Interestingly, current understandings of 
metabolic syndrome have suggested that metabolic syndrome is associated 
with chronic low-grade inflammation [8]. The mechanism remains 
uncertain, but it involves proinflammatory cytokines such as tumor 
necrosis factor-α (TNF-α) and interleukin (IL)-6 which contributes to the 
insulin resistance, central obesity, dyslipidemia, and hypertension [8,9].
Despite the increased prevalence in rheumatic diseases, few studies 
have reported the correlation of SpA’ disease activity and functional 
score to metabolic syndrome with various outcomes [6,7,10-12]. 
However, as SpA’ disease activity score such as bath-AS ankylosing 
spondylitis disease activity index (BASDAI) is dependent to subject’s 
psychological and functional state, it may not reflect the severity 
of SpA [13,14]. Radiographic assessment can be used to assess the 
severity of SpA using modified Stoke Ankylosing Spondylitis Spinal 
Score (mSASSS) [15]. Furthermore, assessing radiographic damage 
can evaluate therapy response, the progression of the disease, and 
associated with magnetic resonance imaging [16]. This study aimed 
to investigate the correlation of radiographic damage, measured with 
mSASSS score with metabolic syndrome in SpA patients.
METHODS
This study is a cross-sectional study conducted from July 2018 to 
October 2018 in Rheumatology Outpatient installation Dr. Soetomo 
General Hospital Surabaya, an A class hospital with consecutive 
sampling technique to recruit the subject. This study has been approved 
by the Ethics Committee of Dr. Soetomo General Hospital on July 10, 
2018, with reference number: 0385/KEPK/VII/2018.
Study population
Consecutive patients (n=33; 10 males and 23 females; mean 
age 48.18±12.27 years) attending the Rheumatology Outpatient 
Department of Dr. Soetomo General Hospital Surabaya between July 
2018 and September 2018, were enrolled in the study. All patients 
fulfilled the ASAS 2010 criteria for SpA [1]. The exclusion criteria in 
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this study are smoking, previous alcohol consumption, chronic kidney 
disease, previous medications (glucocorticoid and anti-TNFα), history 
of malignancy, infection (HIV and hepatitis), and other autoimmune 
diseases. The median of disease duration was 4 years (0–43 years) and 
six patients were diagnosed with SpA at the time of the recruitment. 
Nineteen patients were taking sulfasalazine with median dose 
1000 mg/day (500–2000 mg/day) and eight patients were taking 
methotrexate with median dose 10 mg/week (7.5–10 mg/weekly). 
Fourteen patients were taking Anti-hypertensive drugs (angiotensin-
converting enzyme inhibitor, Angiotensin receptor blocker, calcium 
channel blocker, β-blocker, or combination therapy), 19 patients were 
taking dyslipidemia drugs (statins or fibrates), and four patients were 
taking oral hypoglycemic agents (biguanides).
mSASSS score
Radiography assessment was measured using mSASSS score. There are 
two components which are evaluated in mSASSS score, the anterior 
vertebrae which consist of the lower border of C2 to the upper border 
of Th1 and the lumbar vertebrae which consist of the lower border of 
Th12 to the upper border of S1 combined to 24 vertebrae segments at 
a lateral view. The vertebrae segments were evaluated for the presence 
of erosion and/or sclerosis and/or squaring (1 point), syndesmophyte 
(2 points), and bridging syndesmophytes (three points). The total score 
ranges from 0 to 72 [15]. The radiology assessment was performed 
by two rheumatologists (Awalia and Lita Diah) who were blinded to 
demographic and clinical manifestations. Both readers scored the 
radiography assessment at the same time and registered the changes 
of vertebrae segments separately; therefore, both scores could be 
computed.
Metabolic syndrome
Metabolic syndrome was assessed with National Cholesterol Education 
Program-Adult Treatment Panel (NCEP)-ATP III criteria. According to 
NCEP-ATP III, metabolic syndrome is defined as the presence of minimal 
three of the following five risk factors such as (1) central obesity, (2) 
elevated triglycerides (>150 mg/dL) or previous dyslipidemia medication, 
(3) fasting glucose >100 mg/dL or previous diabetes medication, (4) 
blood pressure >130/80 mmHg, and (5) high-density lipoprotein (HDL) 
<40 mg/dL for male and <50 mg/dL for female [17]. As for central 
obesity, we used the modified criteria of central obesity based on waist 
circumference >90 cm for male and >80 cm for female or body mass index 
for Indonesian populations which defines overweight at 23.0–24.9 kg/m2, 
obese I at 25.0–29.9 kg/m2, and obese II at ≥30 kg/m2 [18,19].
Statistical analysis
The statistical analysis was made by SPSS v21.0 software for MacOSX. 
Interobserver analysis of mSASSS score to validate the mSASSS score 
was performed with Cohen-Kappa analysis. Shapiro–Wilk test was used 
to test the normality of the mSASSS score, followed with Mann-Whitney 
U-test for mean differences of mSASSS score based on the presence of 
the metabolic syndrome. Spearman’s rank correlation was used for 
correlation analysis between mSASSS score and metabolic syndrome 
and the number of metabolic syndrome component.
RESULTS
Demography
There were 33 SpA patients who visited the rheumatology outpatient 
department from July to October 2018 consisted of 23 females and 
10 males. There were 6 (18.1%) newly diagnosed SpA patients; 
therefore, 27 patients had a history of conventional synthetic disease-
modifying anti-rheumatic drug (csDMARDs), with 8 patients (24.2%) 
on methotrexate, and 19 patients (57.6%) on sulfasalazine. No patients 
had a history of metabolic syndrome before diagnosed with SpA, 
smoking, alcohol consumption, chronic kidney disease, or anti-TNFα 
medication. Table 1 shows the basic characteristics of the subjects.
Prevalence of metabolic syndrome components in SpA patients
Fig 1 shows the prevalence of each component of metabolic syndrome 
in SpA patients. Central obesity was the most frequent metabolic 
syndrome component found in this study with a prevalence of 67%, 
followed with decreased HDL-cholesterol and impaired glucose 
tolerance. When we classified the patients with central obesity 
according to their body mass index (BMI) for Indonesian populations, 
we found that 92% met the obese criteria (10 with obese I and 10 with 
obese II) and 8% (two patients) met the overweight criteria.
About 42% (14 patients) of the patients met the criteria of elevated 
blood pressure or had an antihypertensive drugs history before. When 
we classified patients with elevated blood pressure according to their 
blood pressure with JNC VII criteria, we found that 42% (6 out of 14) met 
the criteria of hypertension Stage I, 29% (4 out of 14) met the criteria of 
hypertension Stage II, and 29% (4 out of 14) had a normal blood pressure.
The prevalence of impaired glucose tolerance was 46% (15 patients) 
in this study, with 27% (4 out of 15) had already been diagnosed 
with type 2 diabetes mellitus. All patients with diabetes received oral 
antidiabetic drugs (biguanides).
The prevalence of elevated triglycerides was 42% (14 patients) in this 
study. All patients with elevated triglycerides were on statins. When we 
classified the patients according to their triglycerides level with NCEP-ATP 
III classification, we found that 43% (6 out of 14) were on borderline-high 
triglycerides (150–199 mg/dL), 43% (6 out of 14) were on high triglycerides 
(200–499 mg/dL), and 14% (2 out of 14) were on normal triglycerides level.
The prevalence of decreased HDL-cholesterol was 58% (19 patients) in 
this study with 73.7% (14 out of 19) were on statins. When we classified 
the patients according to their HDL-cholesterol level with NCEP-ATP 
Fig. 1: Prevalence of the metabolic syndrome components in 
spondyloarthritis patients
Table 1: Basic characteristics of the study
Parameter Value
Age (years) 50 (22–72)
Waist circumference (cm) 88 (68–108)
Body Mass Index (kg/m2) 26.45 (17.48–36.07)
Blood pressure
Systolic (mmHg) 120 (100–170)
Diastolic (mmHg) 80 (70–90)
Hemoglobin (g/dL) 12.7 (9.3–15.9)
Leukocytes (µ/L) 7910 (3490–14450)
Platelets (µ/L) 326,000 (206,000–555,000)
Fasting glucose concentration 
(mg/dL)
97 (78–284)
Total cholesterol (mg/dL) 194 (115–255)
Triglycerides (mg/dL) 115 (45–372)
HDL-cholesterol (mg/dL) 47 (31–99)
LDL-cholesterol (mg/dL) 118 (46–157)
Duration of disease (years) 4 (1–43)
mSASSS score 23 (9–60)
On anti-hypertensive (%) 14 (42)
On statins (%) 14 (42)
On oral antidiabetic drugs (%) 4 (12)
mSASSS: Modified stoke ankylosing spondylitis spinal score
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III classification, we found that 47% (9 out of 19) were on low level 
(<40 mg/dL), 47% (9 out of 19) were on normal level, and 6% (1 out of 
19) were on a high level of HDL-cholesterol (>60 mg/dL).
Prevalence of metabolic syndrome in SpA patients
The prevalence of metabolic syndrome in this study was 54.5% 
(18 out of 33 patients) according to the NCEP-ATP III classification of 
metabolic syndrome modified for Indonesian populations. When we 
split the patients based on metabolic syndrome diagnosis, we found 
that 44.4% (8 out of 18) had three components of metabolic syndrome, 
38.9% (7 out of 18) had four components of metabolic syndrome, and 
16.7% (3 out of 18) had five components of metabolic syndrome as 
shown in Fig. 2.
Table 2 describes the metabolic syndrome parameters in SpA 
patients according to the presence of the metabolic syndrome. When 
we classified the patients according to the presence of metabolic 
syndrome, we found that patients with metabolic syndrome were 
significantly older (p=0.003) and had a longer duration of diseases 
(p=0.000). All patients with metabolic syndrome had central obesity 
(100%), had a significantly greater waist circumference (p=0.002), 
and BMI (p=0.000) compared with patients without metabolic 
syndrome.
Elevated blood pressure was observed in 66.67% (12) patients with 
metabolic syndrome; however, there were no significant differences 
in systolic and diastolic blood pressure in patients with and without 
metabolic syndrome (p=0.213 and p=0.185, respectively).
Impaired glucose tolerance was more prevalent in patients with 
metabolic syndrome (61.5%) compared to those without metabolic 
syndrome (13.3%). When we compared the fasting glucose 
concentration, we found a higher glucose concentration in patients with 
metabolic syndrome than those without metabolic syndrome (p=0.000).
Increased triglycerides were observed in 61.5% (11) patients with 
metabolic syndrome, compared to 26.7% (4) in patients without 
metabolic syndrome. There were no significant differences in 
triglycerides level in patients with and without metabolic syndrome 
(p=0.093). Similarly, the prevalence of decreased HDL-cholesterol 
was higher in patients with metabolic syndrome (77.8%) compared 
to patients without metabolic syndrome (33.3%). There were no 
differences in HDL-cholesterol levels in patients with or without 
metabolic syndrome (p=0.128).
mSASSS score
The median score of mSASSS score in this study was 23, as shown 
in Table 1 with interobserver agreement calculated with Cohen-
Kappa’s method κ=0.93, p=0.00. When we compared the mSASSS 
score according to the presence of metabolic syndrome, we found that 
patients with metabolic syndrome had higher mSASSS score compared 
to those without metabolic syndrome (p=0.004).
Correlation of mSASSS score and metabolic syndrome in SpA 
patients
Correlation of mSASSS score and metabolic syndrome was calculated 
with Spearman correlations. We found a moderate correlation between 
mSASSS score and metabolic syndrome (p=0.510, p=0.002). We also 
found a weak correlation between mSASSS core and the number of 
metabolic syndrome components (p=0.448, p=0.009)
DISCUSSION
SpA is a chronic inflammatory disease with various clinical 
manifestations, ranging from ankylosing spondylitis to undifferentiated 
arthritis. It affects male predominantly with male: female ratio 2–3:1 
[20]. However, female was more predominant in this study, accounts 
for 67% subjects in this study with an average age 48 years old. This 
supports the previous study which reported that the male: female ratio 
Fig. 2: The distribution of metabolic syndrome components 
according to metabolic syndrome
Table 2: Characteristic of spondyloarthritis patients according to the presence of the metabolic syndrome
Parameter Metabolic syndrome p
Yes (n=18) No (n=15)
Sex
Male (%) 4 (22.2) 6 (40) 0.003*
Female (%) 14 (77.8) 9 (60)
Age (years) 52 (39–72) 44 (22–63)
Central obesity (%) 18 (100) 4 (26.7) 0.002*
0.000*Waist circumference (cm) 91.5 (82–108) 77 (68–106)
Body mass index (kg/m2) 30.06 (23.63–36.07) 21.63 (17.48–31.25)
Elevated blood pressure (%) 12 (66.67) 2 (13.3) 0.213
0.185Systolic (mmHg) 135 (100–170) 120 (110–160)
Diastolic (mmHg) 80 (70–90) 80 (70–90)
Impaired glucose tolerance (%) 11 (61.5) 2 (13.3) 0.001*
Fasting glucose concentration (mg/dL) 103 (86–284) 93 (78–103)
Increased triglycerides (%) 10 (55.6) 4 (26.7) 0.093
Triglycerides (mg/dL) 142.5 (60–372) 104 (45–203)
Decreased HDL-cholesterol (%) 14 (77.8) 5 (33.3) 0.128
HDL-cholesterol (mg/dL) 46 (31–57) 50 (32–99)
Duration of disease (years) 7.5 (1–43) 2.25 (1.25–7.25) 0.000*
mSASSS score 26 (18–60) 20 (9–29) 0.004*
*Significant with Mann–Whitney U-test analysis (p<0.05). mSASSS: Modified stoke ankylosing spondylitis spinal score
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is equal in older populations (45 years old) and female was associated 
with lower quality of life and more functional limitations despite 
lower degrees of radiographical damage [21,22]. The reason female 
was predominant in this study because our study location is referral 
hospital. Thereby, our cases were difficult cases which is commonly 
found in female with as (Skare et al, 2012).
The prevalence of metabolic syndrome in this study was 54.5%, which 
was higher compared to the prevalence of metabolic syndrome in a 
healthy population that visited primary health care in Jakarta, which 
was 28.4% [23]. This finding supports previous studies which reported 
that the prevalence of metabolic syndrome in SpA populations is higher 
than the healthy population [3,24] Compared to other studies, Malesci 
et al. reported that the prevalence of metabolic syndrome in SpA patients 
in Italy was 45.8% [6]. Maia et al., which observed metabolic syndrome 
in Brazilian ankylosing spondylitis patients and Papadakis et al., which 
observed metabolic syndrome in male Greek ankylosing spondylitis 
patients reported that the prevalence of metabolic syndrome was 27% 
and 34.9%, respectively [7,11]. The differences between this study and 
previous studies might be due to treatment differences because all 
of the patients in this study received csDMARDs which did not affect 
metabolic syndrome’s parameters directly like anti-TNFα which was 
used in some of the previous studies [25].
Analyzing the component of metabolic syndrome, central obesity was 
the most common metabolic syndrome’s component found in this study, 
followed by decreased HDL-cholesterol and impaired glucose tolerance. 
These findings are different from previous studies since elevated blood 
pressure was the more prevalent metabolic syndrome’s component. 
This might be due to the predominant gender differences in our study 
in which female was the more predominant, with average age 48 years, 
and 69.6% of the female were in the menopause period. Menopause 
is associated with hyperandrogenemia which associated with insulin 
resistance and abdominal fat disposition [26].
When we analyzed the patients according to the presence of metabolic 
syndrome, we found that central obesity was still the most prevalent 
metabolic syndrome component in SpA patients with metabolic 
syndrome followed by decreased HDL-cholesterol, elevated blood 
pressure, and impaired glucose tolerance. These findings support 
previous studies which reported that SpA patients with metabolic 
syndrome were older and had more cardiovascular comorbidities 
than those who did not have metabolic syndrome [7,11]. Because all 
patients in this study were not on anti-TNFα, we thought that chronic 
inflammation due to TNF-α activation might have a part in the adverse 
metabolic parameter in this study [9,24].
To the best of our knowledge, this is the first study which observed 
the mSASSS score in Indonesian population. The average mSASSS 
score in this study was higher than the previous studies indicated 
that there was more radiographical damage in our patients [15,27]. 
This might due to the nature of SpA, which is chronic progressive 
and patient’s characteristics in this study. All patients in this study 
were referral cases, so the possibility of late referral cases needed 
to be accounted [28]. When we analyzed the mSASSS score based 
on metabolic syndrome, we found that the average mSASSS score in 
patients with metabolic syndrome was significantly higher than those 
who did not have metabolic syndrome. This finding is the first one 
who observed mSASSS score in patients with metabolic syndrome. 
This supports the hypothesis that inflammation in the enthesis would 
increase the activation of IL-17, which further activates the IL-23/IL-17 
axis [29]. Golden et al. reported that activation of IL-23/IL-17 axis in 
enthesis would not only affect local inflammation but also associated 
with extra-articular complications of SpA [30].
This is the first study which observed the positive correlation of mSASSS 
score and metabolic syndrome and number of metabolic syndrome 
components in SpA patients. These findings supported the findings 
of Papadakis et al., in male Greek ankylosing spondylitis patients 
and Alonso-Blanco Morales et al., in Spanish ankylosing spondylitis 
patients [7,10]. However, previous studies used other methods such 
as BASDAI and BASFI in which both methods evaluate disease activity 
from the patient’s perception of their disease [31,32]. Thus, we thought 
that the severity of inflammation evaluated with mSASSS score was 
more objective to evaluate the duration of long-term inflammation in 
SpA; however, further studies are needed to evaluate the relationships 
between mSASSS score and long-term complication of SpA.
This study has some limitations. We analyzed small numbers of patients 
with cross-sectional design in relatively limited time; therefore, the 
cause-effect relationships between chronic inflammation in SpA and 
metabolic syndrome could not be determined. The location of this study 
is in A class hospital; therefore, all patients were referral cases, and it 
could affect the higher mSASSS score in this study.
CONCLUSION
Our findings showed that the greater prevalence of metabolic syndrome 
in chronic inflammatory diseases, in this case, was SpA. The correlation 
of radiographical damage evaluated by mSASSS score with metabolic 
syndrome and number of metabolic syndrome components suggested 
the role of inflammation to the pathogenesis of metabolic syndrome in 
SpA patients. Early diagnosis and treatment of metabolic syndrome in 
SpA patients are needed to prevent cardiovascular complications.
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